Lead(II,IV) oxide

Claritas Pharmaceuticals Issues Letter to Shareholders

Retrieved on: 
Tuesday, May 11, 2021
Chemistry, Physical sciences, Natural sciences, GABAA receptor positive allosteric modulators, Oxides, Gaseous signaling molecules, Nitrogen cycle, Orphan drugs, Nitric oxide, Lead(II,IV) oxide, Nitric oxide, Lanthanum

Through its Australian subsidiary, Claritas applied for refunds for R&D expenses incurred in 2018 and 2019.

Key Points: 
  • Through its Australian subsidiary, Claritas applied for refunds for R&D expenses incurred in 2018 and 2019.
  • In July and September 2020, Claritas received R&D refunds of AUD $1,376,000 and AUD $1,817,000, respectively.
  • We have brought together a team of internationally renowned experts in nitric oxide science, and our goal is to position the Company as the leader in nitric oxide pharmaceuticals.
  • Our goal for 2021 is to complete our Phase 1 study in Australia demonstrating that R-107 is safe in humans.

Global Inhaled Nitric Oxide Markets, 2020-2027 - Ongoing R&D Activities Leading to New Application Areas in the Healthcare Industry

Retrieved on: 
Friday, March 26, 2021
Chemistry, Physical sciences, Chemical compounds, Oxides, Gaseous signaling molecules, Nitrogen cycle, GABAA receptor positive allosteric modulators, NMDA receptor antagonists, Nitric oxide, Lead(II,IV) oxide, Biological functions of nitric oxide

The global inhaled nitric oxide market was valued at $634.4 million in 2019 and is estimated to reach $1,180.98 million by 2027, registering a CAGR of 8.1% from 2020-2027.

Key Points: 
  • The global inhaled nitric oxide market was valued at $634.4 million in 2019 and is estimated to reach $1,180.98 million by 2027, registering a CAGR of 8.1% from 2020-2027.
  • Nitric oxide (iNO) is selective pulmonary vasodilation and is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture nitric oxide delivery system.
  • Further, clinical trials evaluating the use of inhaled nitric oxide for numerous indications are ongoing.
  • Conversely, ongoing R&D activities leading to new application areas in the healthcare industry are expected to provide lucrative opportunities for the expansion of the global market in the near future.

New Publication Explores Hidden Costs of Tank-Based Inhaled Nitric Oxide Delivery Systems

Retrieved on: 
Thursday, March 11, 2021
Chemistry, Physical sciences, Chemical compounds, Oxides, Gaseous signaling molecules, Nitrogen cycle, GABAA receptor positive allosteric modulators, NMDA receptor antagonists, Nitric oxide, Lead(II,IV) oxide, Nitric oxide, Biological functions of nitric oxide

Nitric oxide is a powerful molecule proven to play a critical role in a broad array of biological functions.

Key Points: 
  • Nitric oxide is a powerful molecule proven to play a critical role in a broad array of biological functions.
  • Methemoglobin levels in the blood increase with the dose of nitric oxide; following discontinuation or reduction of nitric oxide, methemoglobin levels return to baseline over a period of hours.
  • This proprietary delivery system eliminates the need for large nitric oxide tanks and the associated logistical burden.
  • VERO Biotech LLC is dedicated to improving the lives of patients by leading the development of innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever inhaled nitric oxide treatment is needed.

EU Iron, Steel Or Aluminium Reservoirs, Tanks, Vats and Similar Containers Market Report 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 3, 2021
Steel, Manufacturing, Chemistry, Physical sciences, Chemical compounds, Transition metal oxides, Oxides, Chemical elements, Transition metals, Pigment, Cobalt, Oxide, Lead(II,IV) oxide, Iron oxide

The "EU - Iron, Steel Or Aluminium Reservoirs, Tanks, Vats and Similar Containers - Market Report.

Key Points: 
  • The "EU - Iron, Steel Or Aluminium Reservoirs, Tanks, Vats and Similar Containers - Market Report.
  • This report concentrates on the EU iron oxide pigments market, providing a detailed study and the most recent data on its market size and volume, EU trade, price dynamics, domestic production, and turnover in the industry.
  • The market trends section reveals the main issues and uncertainties concerning the industry, while the medium-term forecast uncovers market perspectives.
  • Iron oxide pigments market size and value;
    EU production, split by EU Member States;
    Iron oxide pigments production by type;
    Profiles of the leading companies;
    Prices for iron oxide pigments (producer, import and export);
    Trade structure and market channels;
    Iron oxide pigments market outlook to 2025;

VERO Biotech Receives US FDA Approval of GENOSYL® for the Delivery of Inhaled Nitric Oxide

Retrieved on: 
Friday, December 20, 2019
Chemistry, Physical sciences, Chemical compounds, Oxides, Gaseous signaling molecules, Nitrogen cycle, Neurotransmitters, Nitric oxide, Nitric oxide, Lead(II,IV) oxide

"FDA approval is a major milestone for VERO Biotech and represents an alternative technology within the inhaled nitric oxide market," said Brent V. Furse, President and Chief Executive Officer.

Key Points: 
  • "FDA approval is a major milestone for VERO Biotech and represents an alternative technology within the inhaled nitric oxide market," said Brent V. Furse, President and Chief Executive Officer.
  • "The pediatric respiratory community eagerly looks forward to additional options of inhaled nitric oxide delivery that GENOSYL DS brings to our standard of care."
  • Currently, the only way to provide inhaled nitric oxide is via large, pressurized gas cylinders and complicated delivery systems.
  • VERO Biotech LLC is dedicated to improving the lives of patients by leading the development of innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever inhaled nitric oxide treatment is needed.